Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

By In The News
December 13, 2021 in The Headlines

Followers 0

Recommended Posts

In The News

Posted December 13, 2021

- Share

Posted December 13, 2021

NEWARK, Del. and NANJING, China, Dec. 13, 2021 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global, clinical stage biotechnology company, today announced that Biosion and OBI Pharma Inc. (4174.TWO) ("OBI Pharma") have signed an exclusive license agreement under which OBI Pharma will be...

View the full article

Link to comment

Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign in

Already have an account? Sign in here.

Followers 0

Go to topic listing

Most Contributions
1. In The News
  221112
2. Jaydee
  17346
3. deicer
  12756
4. Kip Powick
  12274
5. dagger
  9601
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  271.4k
- Total Posts
  
  562k

Sign In

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

Recommended Posts

In The News

Link to comment

Share on other sites

Create an account or sign in to comment

Create an account

Sign in

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support